Lead Product(s): Phenylephrine
Therapeutic Area: Cardiology/Vascular Diseases
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Xellia Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 21, 2020
Agreement significantly expands biorphen commercial footprint and provides access to institutions that prefer ready-to-use injectable formulations.